
    
      prospective, randomized, controlled study on post-cardiac surgery patients , included two
      groups, over one year period. The first group was administered intravenous (IV) amikacin 20
      mg/kg once daily. The second group was prescribed amikacin nebulizer 400 mg twice daily. Both
      groups were co-administered intravenous (IV) piperacillin/tazobactam empirically.
    
  